A screen of FDA-approved drugs identifies inhibitors of protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-3)

Protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-3) is highly expressed in a variety of cancers, where it promotes tumor cell migration and metastasis leading to poor prognosis. Despite its clinical significance, small molecule inhibitors of PRL-3 are lacking. Here, we screened 1443 FDA-approved drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivas, Dylan R., Dela Cerna, Mark Vincent C., Smith, Caroline N., Sampathi, Shilpa, Patty, Blaine G., Lee, Donghan, Blackburn, Jessica S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119466/
https://www.ncbi.nlm.nih.gov/pubmed/33986418
http://dx.doi.org/10.1038/s41598-021-89668-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119466/
https://www.ncbi.nlm.nih.gov/pubmed/33986418
http://dx.doi.org/10.1038/s41598-021-89668-5

Ejemplares similares